Structure Therapeutics (GPCR) announced the first patients have been dosed in the randomized, double-blind, placebo-controlled Phase 2b ACCESS clinical study evaluating GSBR-1290 in participants living with obesity, or overweight with a weight-related comorbidity. GSBR-1290 is an orally-available, nonpeptide small molecule glucagon-like-peptide-1 receptor agonist that has demonstrated competitive weight loss and generally favorable safety and tolerability results in previous studies with once-daily dosing.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GPCR:
- Is GPCR a Buy, Before Earnings?
- 3 Best Stocks to Buy Now, 9/23/2024, According to Top Analysts
- Structure Therapeutics initiated with an Overweight at Morgan Stanley
- Structure Therapeutics Announces Key Executive Leadership Changes
- Structure Therapeutics CMO Mark Bach to leave role, Blai Coll to succed
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
